The NC Group, which controls the pharmaceutical company EMS, owned by businessman Carlos Sanchez, won the sale process carried out by the French company Sanofi and became the new owner of Medley. The Sanchez family company paid US$600 million (R$3.175 billion) for the generic drug brand, a value higher than the initially projected US$500 million.
The market already saw the Sanchez family's pharmaceutical company with a slight advantage in the competition, having submitted one of the highest offers among the candidates. Aché was also considered a potential buyer, followed by the Indian company Sun Pharma, which already operates in Brazil with the generic drug brand Ranbaxy.
EMS's advantage lay in the synergy of the business, especially in relation to logistics, since Medley's factory in Campinas (SP) is less than 20 kilometers from the industrial park of the company led by Carlos Sanchez, in Hortolândia (SP).
EMS, however, has already recognized the need for a new factory and will build a new unit for Medley, in addition to its existing manufacturing plant in Campinas. The location will depend not only on approval from CADE (Brazil's antitrust authority) but also on the course of tax reform.
The company also decided that it will expand the product portfolio of the newly acquired generic drug brand.
In 2025, Medley recorded revenues of R$1.3 billion, with EBITDA close to R$200 million. Sanofi acquired the Brazilian pharmaceutical company in 2009 from the Negrão family for R$1.5 billion.
The two operations will be maintained independently. The contract was signed on the morning of Friday, March 6, and will now be reviewed by the Administrative Council for Economic Defense (Cade).
(More information coming soon)
